Breaking biological barriers: Engineering polymeric nanoparticles for cancer therapy
Source abstract
Abstract
Polymeric nanoparticles (PNPs) have evolved over the past few decades as promising vehicles to deliver drugs to treat cancer. However, their clinical application remains limited mainly due to several biological obstacles. These include rapid clearance from the bloodstream, complex hemorheological dynamics, suboptimal biodistribution , limited tumor accumulation and extravasation, inefficient cellular internalization and trafficking, and offsite toxicity. How can we carefully tune the physicochemical properties of PNPs to break these barriers? This review answers this question by comprehensively and critically examining recent advances and trends in engineering the physicochemical properties of PNPs to enhance their efficacy in cancer drug delivery. It sheds light on the underpinning mechanisms regulated by size, shape, and surface chemistry critical in overcoming heterogeneous biological barriers. Synergistic effects and the interplay between these physicochemical properties are discussed in detail. The types of PNPs, based on form, morphology, and fabrication strategies, are critically reviewed and evaluated according to their physicochemical properties, which directly impact the efficacy of the drug delivery systems and their fate upon administration. The review concludes by proposing design principles and future research directions to enhance the clinical translation of PNPs and their advancement towards more effective cancer treatments.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Graphene and Nanomaterials Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Rational combinations of targeted cancer therapies: background, advances and challenges10.1038/s41573-022-00615-z ↗
2. RNA-based pharmacotherapy for tumors: from bench to clinic and back10.1016/j.biopha.2020.109997 ↗
3. Predicting tumour radiosensitivity to deliver precision radiotherapy10.1038/s41571-022-00709-y ↗
4. Poly Ethylene Glycol (PEG)-based hydrogels for drug delivery in cancer therapy
5. Nanobiomaterials used in cancer therapy: An up-to-date overview10.3390/molecules24193547 ↗
6. Rising horizon in circumventing multidrug resistance in chemotherapy with nanotechnology10.1016/j.msec.2019.04.005 ↗
7. Nanomedicine tumor targeting10.1002/adma.202312169 ↗
8. Recent advances in active targeting of nanomaterials for anticancer drug delivery10.1016/j.cis.2021.102509 ↗
9. Engineering precision nanoparticles for drug delivery10.1038/s41573-020-0090-8 ↗
10. Polymeric nanoparticles: production, characterization, toxicology and ecotoxicology10.3390/molecules25163731 ↗
11. Polymeric nanoparticles as therapeutic agents against coronavirus disease10.1007/s11051-022-05396-5 ↗
12. Stable polymer nanoparticles with exceptionally high drug loading by sequential nanoprecipitation10.1002/ange.201913539 ↗
13. pH-responsive charge switchable PEGylated ε-poly-l-lysine polymeric nanoparticles-assisted combination therapy for improving breast cancer treatment10.1016/j.jconrel.2020.07.030 ↗
14. Diselenide-containing nonionic gemini polymeric micelles as a smart redox-responsive carrier for potential programmable drug release10.1016/j.polymer.2020.122551 ↗
15. A smart drug delivery system responsive to pH/enzyme stimuli based on hydrophobic modified sodium alginate10.1016/j.eurpolymj.2020.109779 ↗
16. Temperature- and pH-responsive star polymers as nanocarriers with potential for in vivo agrochemical delivery10.1021/acsnano.0c03140 ↗
17. A review on polymer and lipid-based nanocarriers and its application to nano-pharmaceutical and food-based systems10.3389/fnut.2021.783831 ↗
18. The importance of poly(ethylene glycol) alternatives for overcoming PEG immunogenicity in drug delivery and bioconjugation10.3390/polym12020298 ↗
19. Exploring the relationship between anti-PEG IgM behaviors and PEGylated nanoparticles and its significance for accelerated blood clearance10.1016/j.jconrel.2016.05.010 ↗
20. Anti-PEG IgM response against PEGylated liposomes in mice and rats10.3390/pharmaceutics3010001 ↗
21. Basophil reactivity to BNT162b2 is mediated by PEGylated lipid nanoparticles in patients with PEG allergy10.1016/j.jaci.2021.04.032 ↗
22. Correlation between long-term stability of solid lipid nanoparticles (SLN™) and crystallinity of the lipid phase10.1016/S0939-6411(98)00074-5 ↗
23. A brief review on solid lipid nanoparticles: part and parcel of contemporary drug delivery systems10.1039/D0RA03491F ↗
24. Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs10.1038/s41578-022-00529-7 ↗
25. Polymeric nanoparticles for drug delivery10.1021/acs.chemrev.3c00705 ↗
26. Surface Bio-engineered Polymeric Nanoparticles
27. Impact of Polyethylene Glycol (PEG) conformations on the in vivo fate and drug release behavior of PEGylated core-cross-linked polymeric nanoparticles10.1021/acs.biomac.2c00730 ↗
28. A review of nanoparticle drug delivery systems responsive to endogenous breast cancer microenvironment10.1016/j.ejpb.2021.05.029 ↗
29. Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine10.1016/j.addr.2019.04.008 ↗
30. Thiol-disulfide exchange as a route for endosomal escape of polymeric nanoparticles10.1002/ange.202209227 ↗
31. Nanomedicine applied to translational oncology: a future perspective on cancer treatment10.1016/j.nano.2015.08.006 ↗
32. Eligard® 6: a new form of treatment for prostate cancer10.1016/j.eursup.2006.08.006 ↗
33. ELIGANT: a Phase 4, interventional, safety study of leuprorelin acetate (ELIGARD®) in Asian men with prostate cancer10.21037/tau-21-723 ↗
34. Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer10.1093/annonc/mdm374 ↗
35. An open-label, multicenter, phase I trial of a cremophor-free, polymeric micelle formulation of paclitaxel combined with carboplatin as a first-line treatment for advanced ovarian cancer: a Korean Gynecologic Oncology Group study10.3802/jgo.2017.28.e26 ↗
36. An open-label, randomized, parallel, phase iii trial evaluating the efficacy and safety of polymeric micelle-formulated paclitaxel compared to conventional cremophor EL-based paclitaxel for recurrent or metastatic HER2-negative breast cancer
37. Multicenter trial for safety and toxicity of a nanoparticle docetaxel formulation in breast cancer10.1093/annonc/mdy426.010 ↗
38. Clinical and economic implications of the use of nanoparticle paclitaxel (Nanoxel) in India10.1093/annonc/mdt322 ↗
39. Paclitaxel injection concentrate for nanodispersion versus nab-paclitaxel in women with metastatic breast cancer: a multicenter, randomized, comparative phase II/III study10.1007/s10549-016-3736-9 ↗
40. The battle of “nano” paclitaxel10.1016/j.addr.2017.02.003 ↗
41. A randomized phase III trial in patients with recurrent platinum sensitive ovarian cancer comparing efficacy and safety of paclitaxel micellar and Cremophor EL-paclitaxel10.1016/j.ygyno.2019.11.034 ↗
42. Oasmia Pharmaceutical Receives Approval from European Commission for Apealea® (paclitaxel micellar) in the European Union, Vivesto, 2018.
43. In vitro microfluidic models of tumor microenvironment to screen transport of drugs and nanoparticles
44. The effects of protein corona on in vivo fate of nanocarriers10.1016/j.addr.2022.114356 ↗
45. Nanoparticle based medicines: approaches for evading and manipulating the mononuclear phagocyte system and potential for clinical translation, Biomaterials
46. Size-tunable PEG-grafted copolymers as a polymeric nanoruler for passive targeting muscle tissues10.1016/j.jconrel.2022.05.030 ↗
47. Detachment of ligands from nanoparticle surface under flow and endothelial cell contact: Assessment using microfluidic devices10.1002/btm2.10089 ↗
48. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology10.1038/nnano.2013.181 ↗
49. The impact of protein corona on the behavior and targeting capability of nanoparticle-based delivery system10.1016/j.ijpharm.2018.10.011 ↗
50. Analysis of nanoparticle delivery to tumours10.1038/natrevmats.2016.14 ↗
51. Elucidating the influences of size, surface chemistry, and dynamic flow on cellular association of nanoparticles made by polymerization-induced self-assembly10.1002/smll.201801702 ↗
52. The structural and molecular basis of glomerular filtration10.1161/01.RES.43.3.337 ↗
53. Principles of nanoparticle design for overcoming biological barriers to drug delivery10.1038/nbt.3330 ↗
54. Re-directing nanomedicines to the spleen: a potential technology for peripheral immunomodulation10.1016/j.jconrel.2022.04.005 ↗
55. Biodegradable micro-sized discoidal polymeric particles for lung-targeted delivery system10.1016/j.biomaterials.2019.119331 ↗
56. Nanoparticle-induced complement activation: implications for cancer
57. The tumor microenvironment10.1016/j.cub.2020.06.081 ↗
58. The acidic tumor microenvironment as a driver of cancer10.1146/annurev-physiol-021119-034627 ↗
59. Biomaterials tools to modulate the tumour microenvironment in immunotherapy10.1038/s44222-022-00004-6 ↗
60. Concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs
61. High interstitial fluid pressure—an obstacle in cancer therapy10.1038/nrc1456 ↗
62. Noninvasive detection of extracellular pH in human benign and malignant liver tumors Using CEST MRI10.3389/fonc.2020.578985 ↗
63. Protein delivery into cells using inorganic nanoparticle–protein supramolecular assemblies10.1039/C8CS00008E ↗
64. Key principles and methods for studying the endocytosis of biological and nanoparticle therapeutics10.1038/s41565-021-00858-8 ↗
65. AAGAB Controls AP2 adaptor assembly in clathrin-mediated endocytosis10.1016/j.devcel.2019.06.013 ↗
66. Endocytosis by random initiation and stabilization of clathrin-coated pits10.1016/j.cell.2004.08.017 ↗
67. Endophilin marks and controls a clathrin-independent endocytic pathway10.1038/nature14067 ↗
68. Clathrin-independent endocytosis, retrograde trafficking, and cell polarity10.1016/j.ceb.2020.05.009 ↗
69. Targeted drug delivery system inspired by macropinocytosis10.1016/j.jconrel.2023.06.011 ↗
70. Macropinosome formation by tent pole ruffling in macrophages10.1083/jcb.201804137 ↗
71. Autophagy and macrophage functions: inflammatory response and phagocytosis10.3390/cells9010070 ↗
72. Subversion strategies of lysosomal killing by intracellular pathogens10.1016/j.micres.2023.127503 ↗
73. The mechanisms of nanoparticle delivery to solid tumours10.1038/s44222-024-00154-9 ↗
74. Specific endothelial cells govern nanoparticle entry into solid tumors10.1021/acsnano.1c04510 ↗
75. Real-time imaging reveals local, transient vascular permeability, and tumor cell intravasation stimulated by TIE2hi macrophage–derived VEGFA10.1158/2159-8290.CD-15-0012 ↗
76. Extravasating neutrophils open vascular barrier and improve liposomes delivery to tumors10.1021/acsnano.9b03848 ↗
77. Drug delivery with polymeric nanocarriers—cellular uptake mechanisms10.3390/ma13020366 ↗
78. Albumin-embellished arsenic trioxide-loaded polymeric nanoparticles enhance tumor accumulation and anticancer efficacy via transcytosis for hepatocellular carcinoma therapy10.1208/s12249-022-02254-4 ↗
79. Novel strategies of third level (Organelle-specific) drug targeting: an innovative approach of modern therapeutics
80. The endosomal escape of nanoparticles: toward more efficient cellular delivery10.1021/acs.bioconjchem.8b00732 ↗
81. Challenges and directions in studying cell–cell communication by extracellular vesicles10.1038/s41580-022-00460-3 ↗
82. Smart pH‑responsive nanomedicines for disease therapy
83. Cytotoxicity-related bioeffects induced by nanoparticles: the role of surface chemistry10.3389/fbioe.2019.00414 ↗
84. Oxidative stress: harms and benefits for human health10.1155/2017/8416763 ↗
85. Oxidative stress in cancer therapy: friend or enemy?10.1002/cbic.202100641 ↗
86. Cytotoxic and inflammatory responses of TiO2 nanoparticles on human peripheral blood mononuclear cells10.1002/jat.3342 ↗
87. Targeting autophagy using metallic nanoparticles: a promising strategy for cancer treatment10.1007/s00018-018-2973-y ↗
88. The double-edge sword of autophagy in cancer: from tumor suppression to pro-tumor activity10.3389/fonc.2020.578418 ↗
89. Targeting necroptosis as an alternative strategy in tumor treatment: From drugs to nanoparticles10.1016/j.jconrel.2022.06.060 ↗
90. Interconnections between apoptotic, autophagic and necrotic pathways: implications for cancer therapy development10.1111/jcmm.12001 ↗
91. Structure-based varieties of polymeric nanocarriers and influences of their physicochemical properties on drug delivery profiles10.1002/advs.202105373 ↗
92. Progress in nanomedicine: approved and investigational nanodrugs
93. First-in-class and best-in-class dendrimer nanoplatforms from concept to clinic: Lessons learned moving forward10.1016/j.ejmech.2021.113456 ↗
94. Quantification of intracellular payload release from polymersome nanoparticles10.1038/srep29460 ↗
95. Combining nanoparticle shape modulation and polymersome technology in drug delivery10.1021/acsabm.1c00203 ↗
96. A holistic approach to targeting disease with polymeric nanoparticles10.1038/nrd4503 ↗
97. Polymeric nanoparticles: a study on the preparation variables and characterization methods10.1016/j.msec.2017.06.004 ↗
98. Synthesis of organic nanoparticles10.1016/B978-0-12-415769-9.00004-2 ↗
99. A robust systematic design: optimization and preparation of polymeric nanoparticles of PLGA for docetaxel intravenous delivery
100. A mechanistic study of the formation of polymer nanoparticles by the emulsification-diffusion technique10.1007/s003960050130 ↗